News

Latest News:

mc2_news-image-icon-05

MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

POSTED: September 14, 2022

  • Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated skin diseases
  • First patients dosed in Europe in Phase 2 trial assessing the safety and efficacy ...

    READ FULL ARTICLE >

mc2_news-image-icon-04

MC2 Therapeutics announces breakthrough discovery with the potential to help millions of people suffering from urea associated skin diseases

POSTED: September 1, 2022

  • Breakthrough discovery of a novel biological paradigm for treatment of several urea associated skin diseases
  • MC2 Therapeutics has patented and initiated development of drug candidates for chronic kidney disease associated pruritus ...

    READ FULL ARTICLE >

mc2_news-image-icon-07

Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

POSTED: June 9, 2022

Copenhagen, June 9th 2022 – MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and ...

READ FULL ARTICLE >

Upcoming Events:

February 28th, 2022

MC2 exposure at PCMA Business Forum 2022

READ MORE >

August 11th, 2021

MC2 Therapeutics is proud to support National Psoriasis Action Month

READ MORE >

July 23, 2021

MC2 Therapeutics supports World Sjögren’s Day

READ MORE >